a b s t r a c t a 2 -Adrenoceptors are widely distributed throughout the central nervous system (CNS) and the systemic administration of a 2 -agonists such as dexmedetomidine produces clinically useful, centrally mediated sedation and analgesia; however, these same actions also limit the utility of these agents (ie, unwanted sedative actions). Despite a wealth of data on cellular and synaptic actions of a 2 -agonists in vitro, it is not known which neuronal circuits are modulated in vivo to produce the analgesic effect. To address this issue, we made in vivo recordings of membrane currents and synaptic activities in superficial spinal dorsal horn neurons and examined their responses to systemic dexmedetomidine. We found that dexmedetomidine at doses that produce analgesia (<10 lg/kg) enhanced inhibitory postsynaptic transmission within the superficial dorsal horn without altering excitatory synaptic transmission or evoking direct postsynaptic membrane currents. In contrast, higher doses of dexmedetomidine (>10 lg/kg) induced outward currents by a direct postsynaptic action. The dexmedetomidine-mediated inhibitory postsynaptic current facilitation was not mimicked by spinal application of dexmedetomidine and was absent in spinalized rats, suggesting that it acts at a supraspinal site. Furthermore, it was inhibited by spinal application of the a 1 -antagonist prazosin. In the brainstem, low doses of systemic dexmedetomidine produced an excitation of locus coeruleus neurons. These results suggest that systemic a 2 -adrenoceptor stimulation may facilitate inhibitory synaptic responses in the superficial dorsal horn to produce analgesia mediated by activation of the pontospinal noradrenergic inhibitory system. This novel mechanism may provide new targets for intervention, perhaps allowing analgesic actions to be dissociated from excessive sedation.
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Introduction
Clinically, a 2 -adrenoceptor agonists such as dexmedetomidine are widely used as sedative agents, as adjuncts to anesthesia, and have been noted to produce analgesic effects [9,13,38]. Dexmedetomidine is a potent analgesic, but the accompanying sedation (and hypotension) produced by systemic administration has limited the widespread deployment of a 2 -agonists as analgesics and has prompted investigations to separate these effects. It has been suggested that the sedative action of dexmedetomidine is primarily mediated by inhibition of locus coeruleus (LC) neurons, which has an important role in attention and arousal [2,4,12,15]. There is evidence suggesting that the spinal cord is the principal site for its analgesic action [35, 61] , and previous behavioral studies have shown that intrathecal or epidural dexmedetomidine is anti-nociceptive [3, 18] . However, there is conflicting evidence suggesting that after systemic administration it may act to produce analgesia via an action at the LC [26] .
